Health Care

Health Care Equipment

20 companies under coverage.

Coverage

Health Care Equipment

Globus Medical (GMED)

HOLD. 12-month probability-weighted target $74 (-1% vs spot). P/E Multiple explains 69% of Monte Carlo outcome variance.

GMEDEquity ResearchMonte Carlo

12 October 2026Rating: HOLD · Fair value vs price +4.2%

Equity Research

Stryker Corporation (SYK)

HOLD. 12-month probability-weighted target $309 (+12% vs spot). P/E Multiple explains 69% of Monte Carlo outcome variance.

SYKEquity ResearchMonte Carlo

12 October 2026Rating: HOLD · Fair value vs price +0.2%

Equity Research

LivaNova PLC (LIVN)

HOLD. 12-month probability-weighted target $77 (+1% vs spot). P/E Multiple explains 58% of Monte Carlo outcome variance.

LIVNEquity ResearchMonte Carlo

12 October 2026Rating: HOLD · Fair value vs price -0.5%

Equity Research

Insulet Corporation (PODD)

HOLD. 12-month probability-weighted target $149 (+10% vs spot). P/E Multiple explains 53% of Monte Carlo outcome variance.

PODDEquity ResearchMonte Carlo

12 October 2026Rating: HOLD · Fair value vs price -0.7%

Equity Research

Boston Scientific Corp (BSX)

HOLD. 12-month probability-weighted target $43 (+1% vs spot). P/E Multiple explains 70% of Monte Carlo outcome variance.

BSXEquity ResearchMonte Carlo

12 October 2026Rating: HOLD · Fair value vs price -0.8%

Equity Research

Edwards Lifesciences Corp (EW)

HOLD. 12-month probability-weighted target $86 (+1% vs spot). P/E Multiple explains 76% of Monte Carlo outcome variance.

EWEquity ResearchMonte Carlo

12 October 2026Rating: HOLD · Fair value vs price -4.6%

Equity Research

STERIS plc (STE)

HOLD. 12-month probability-weighted target $207 (-4% vs spot). P/E Multiple explains 60% of Monte Carlo outcome variance.

STEEquity ResearchMonte Carlo

12 October 2026Rating: HOLD · Fair value vs price -8.4%

Equity Research

IDEXX Laboratories Inc (IDXX)

HOLD. 12-month probability-weighted target $534 (+3% vs spot). P/E Multiple explains 75% of Monte Carlo outcome variance.

IDXXEquity ResearchMonte Carlo

12 October 2026Rating: HOLD · Fair value vs price -9.2%

Equity Research

Medtronic PLC (MDT)

HOLD. 12-month probability-weighted target $85 (-4% vs spot). P/E Multiple explains 66% of Monte Carlo outcome variance.

MDTEquity ResearchMonte Carlo

12 October 2026Rating: HOLD · Fair value vs price -11.0%

Equity Research

ResMed Inc (RMD)

SELL. 12-month probability-weighted target $198 (-14% vs spot). P/E Multiple explains 80% of Monte Carlo outcome variance.

RMDEquity ResearchMonte Carlo

12 October 2026Rating: SELL · Fair value vs price -12.7%

Equity Research

GE HealthCare Technologies Inc. (GEHC)

HOLD. 12-month probability-weighted target $62 (-5% vs spot). Gross Margin explains 60% of Monte Carlo outcome variance.

GEHCEquity ResearchMonte Carlo

12 October 2026Rating: HOLD · Fair value vs price -13.1%

Equity Research

Zimmer Biomet Holdings Inc (ZBH)

HOLD. 12-month probability-weighted target $89 (+0% vs spot). P/E Multiple explains 63% of Monte Carlo outcome variance.

ZBHEquity ResearchMonte Carlo

12 October 2026Rating: HOLD · Fair value vs price -13.3%

Equity Research

Abbott Laboratories (ABT)

HOLD. 12-month probability-weighted target $92 (-8% vs spot). P/E Multiple explains 67% of Monte Carlo outcome variance.

ABTEquity ResearchMonte Carlo

12 October 2026Rating: HOLD · Fair value vs price -15.4%

Equity Research

Intuitive Surgical Inc (ISRG)

HOLD. 12-month probability-weighted target $397 (-6% vs spot). P/E Multiple explains 83% of Monte Carlo outcome variance.

ISRGEquity ResearchMonte Carlo

12 October 2026Rating: HOLD · Fair value vs price -17.6%

Equity Research

Bruker Corporation (BRKR)

HOLD. 12-month probability-weighted target $54 (-8% vs spot). Gross Margin explains 64% of Monte Carlo outcome variance.

BRKREquity ResearchMonte Carlo

12 October 2026Rating: HOLD · Fair value vs price -23.2%

Equity Research

DexCom Inc (DXCM)

SELL. 12-month probability-weighted target $65 (-23% vs spot). P/E Multiple explains 67% of Monte Carlo outcome variance.

DXCMEquity ResearchMonte Carlo

12 October 2026Rating: SELL · Fair value vs price -26.2%

Equity Research

Baxter International Inc (BAX)

SELL. 12-month probability-weighted target $20 (-18% vs spot). Gross Margin explains 66% of Monte Carlo outcome variance.

BAXEquity ResearchMonte Carlo

12 October 2026Rating: SELL · Fair value vs price -31.7%

Equity Research

Becton Dickinson and Company (BDX)

SELL. 12-month probability-weighted target $144 (-21% vs spot). P/E Multiple explains 56% of Monte Carlo outcome variance.

BDXEquity ResearchMonte Carlo

12 October 2026Rating: SELL · Fair value vs price -33.6%

Equity Research

Revvity Inc. (RVTY)

SELL. 12-month probability-weighted target $107 (-31% vs spot). P/E Multiple explains 65% of Monte Carlo outcome variance.

RVTYEquity ResearchMonte Carlo

12 October 2026Rating: SELL · Fair value vs price -37.7%

Equity Research

Penumbra Inc (PEN)

Rating suspended since 2026-09-29 — valuation method under review. The rating, price target and expected return are withheld until the name is re-valued; the research on the report page predates the review.

PENEquity ResearchMonte Carlo

12 October 2026Rating: N/A